Relixir Pharmaceuticals Private Limited - Due diligence report

A 360° intelligence report on Relixir Pharmaceuticals Private Limited: trust score, financial health, credit view, compliance, directors, gr…

2011-02-14 Hyderabad, Telangana Active Unlisted Active Compliant
Share
View plans
RP Relixir Pharmaceuticals Private Limited
Full Due-Diligence Report + Documents
  • Unlock all financial figures & 5-year trends
  • Full trust, health & credit-risk scores
  • Director details, charges & MCA documents
₹700 ₹349 50% off New user
Or enjoy up to 50% off with credits View credit packages
Company Credits – Starter
  • One credit unlocks this full due-diligence report
  • Use across any company’s report, anytime
  • Credits valid for 12 months
× ₹700 ₹279 = ₹2,790 60% off
Choose your own credit amount View credit packages

Relixir Pharmaceuticals Private Limited — 360° Intelligence Report

Generated from MCA filings & public records
73/100
Trust Score
Moderate

Relixir Pharmaceuticals Private Limited is assessed as Moderate with a Trust Score of 73/100. Relixir Pharmaceuticals Private Limited is an active private limited indian non-government company incorporated in 2011, operating in the Pharma sector. It was profitable in its latest filed year. Based on MCA filings and public records, it currently shows a moderate compliance risk and moderate financial risk profile.

Report generated on 03 Jul 2026 from the latest processed filings. Relixir Pharmaceuticals Private Limited snapshot & full profile →

Financial Health › Good
Overall Assessment CautionWeakNeutralGoodStrong Strong
Compliance › Good

Automated indicators derived from public MCA / GST / EPFO records - not a credit rating, not investment, legal or financial advice. Spotted an inaccuracy? Report an error.

02

Score Card

Higher is safer · rule-based & explainable
Trust ScoreModerate
73/100
Overall counterparty trust - the headline number of this report.
Compliance ScoreModerate
68/100
Statutory standing - status, filings, auditor, MSME and litigation.
Financial Health ScoreModerate
55/100
Profitability, leverage and liquidity from filed statements.
Credit Risk ScoreCaution Indicated
45/100
Debt capacity, gearing and security cover for lenders.
Director Stability ScoreLow Risk
95/100
Board strength, DIN status, churn and network.
Growth ScoreModerate
50/100
Revenue, profit, asset and hiring momentum.
Distress ScoreModerate
65/100
Early-warning signals - higher means fewer warnings.
03

Financial Intelligence Dashboard

Standalone · 5 filed year(s)

Unlock the full 5-year financial dashboard with charts and year-wise figures.

Get full access

Scores and observations on this page are already computed from the real filings - only the underlying figures are locked.

04

Credit & Compliance Intelligence

Why the scores are what they are
Credit Risk Score: 45/100 Caution Indicated
  • Liabilities ≈ 38% EBITDA - stretched.
  • No open charges - unencumbered balance sheet.
  • Elevated gearing (D/E 1.42).
  • Profitable - internal accruals available.

Charges position: 0 open (-) · 3 satisfied (26.81 cr).

Banking relationships (from registered charges)
LenderChargesAmount
Others3 48.0 cr
Compliance Score: 68/100 Moderate
  • Company status is Active as per MCA.
  • Last balance sheet is for Mar 2023 - filings overdue.
  • Litigation present in 1 court forum(s).
  • 1 active GST registration(s).
Legal cases on record (1)
05

Director Intelligence

Stability score: 95/100
NameDIN / PANDesignationAppointedTenureDIN status
ANIL KUMAR DEVANAPALLI RAMAYA 01234567 Director 01/04/2018 6 yrs Approved
Navaratan Kakani 01234567 Director 01/04/2018 6 yrs Approved
VINUTHA MANDULA 01234567 Director 01/04/2018 6 yrs Approved
  • 3 directors on the board.
  • No disqualified or deactivated DINs.
  • Stable board - no exits in 3 years.
  • Average tenure above 5 years.
06

Ownership & Group Intelligence

As per FY 2022 annual return
Promoter holding
64.27%
Public / other holding
35.73%
Equity shares
12,45,67,890
Equity paid-up
124.5 cr
Promoters on record
4
Ultimate holding entity
-
Subsidiaries
-
Group entities
-
Capital events
32 allotment(s) · 2 transfer(s)

Promoters hold a dominant controlling stake - exact percentages are part of the full report.

Full shareholding pattern, group structure & capital events →

07

Risk Intelligence Center

Growth 50 · Distress 65
Growth signals & trust indicators
Operating for 15+ years.
Active EPFO - real payroll on record.
Active GST registration(s).
Distress signals & risk flags
Revenue declined year-on-year.
Statutory filings appear overdue.
1 court case(s) on record - see the legal section for details.
08

Stakeholder Verdicts

Vendor · Banker · Investor
Vendor due diligence69/100
Review suggested
Suitability as a supplier / customer counterparty.
  • Check the compliance flags before onboarding.
  • 2 distress signal(s) - see Risk Center.
  • Financial filings available for verification.
Banker assessment54/100
Mixed indicators - deeper appraisal suggested
Indicative lending comfort for banks, NBFCs and trade credit.
  • Debt capacity assessed from filed statements.
  • No existing security registered - first-charge position available.
  • Compliance gaps should be priced into terms.
Investor view58/100
Mixed indicators
Growth quality and scalability through an investor lens.
  • No clear growth signals in the filed years.
  • Margin and return trends computable from filings.
  • Management team looks stable.
09

MCA Filings & Events Timeline

Latest 15 events
30 Sep 2023
Last AGM held
Annual general meeting
31 Mar 2023
Latest balance sheet
Filed with ROC
23 Mar 2023
Charge satisfied
Others
30 Apr 2022
Charge created
Others - 1.45 cr
25 Nov 2020
Securities allotted
759297 Equity Shares Without Differential Rights - 75.93 Lakh raised
24 Nov 2020
Securities allotted
759297 Equity Shares Without Differential Rights - 75.93 Lakh raised
23 Nov 2020
Charge created
Others - 70.00 Lakh
13 Oct 2020
Securities allotted
612000 Equity Shares Without Differential Rights - 61.20 Lakh raised
01 Oct 2020
Securities allotted
680000 Equity Shares Without Differential Rights - 68.00 Lakh raised
26 May 2020
Securities allotted
680000 Equity Shares Without Differential Rights - 68.00 Lakh raised
Securities allotted
612000 Equity Shares Without Differential Rights - 61.20 Lakh raised
22 Oct 2019
Director ceased
NISCHAL YACHAMANENI
01 Feb 2019
Director appointed
Navaratan Kakani (Company Secretary)
07 Jan 2019
Securities allotted
280000 Equity Shares Without Differential Rights - 28.00 Lakh raised
31 Oct 2018
Securities allotted
280000 Equity Shares Without Differential Rights - 28.00 Lakh raised
10

Key Observations

Auto-generated from the data above
Debt-to-equity stands at 2.1x - leverage worth monitoring.
Net worth is positive.
3 active director(s) / partner(s); board looks stable and experienced.
1 active GST registration(s) indicate ongoing business operations.
All 3 registered charge(s) stand satisfied - past borrowings repaid.
EPFO-registered employer - verifiable payroll history exists.
Promoters hold a dominant controlling stake as per the FY 2022 annual return.
Capital has been raised through 32 security allotment(s) - amounts available in the full report.
11

Peers & Related Companies

Full peer comparison →
CompanyCINLocation
Chemtech Alkoxides Private Limited U24117TG2007PTC053479 Hyderabad, Telangana, India
Aril Bioscience Private Limited U24304MH2018PTC304667 Mumbai, Maharashtra, India
Biogeny Diagnostics U24299GJ2009PTC057520 Navsari, Gujarat, India
Ramkamal Chemicals Private Limited U99999MH1996PTC100977 Mumbai, Maharashtra, India
Aashka Formulation Private Limited U36100GJ2018PTC101962 Kalol, Gujarat, India
Dhehradun Calcium Minerals Private Limited U14292RJ2004PTC019954 Jodhpur, Rajasthan, India
Terramera U40104TN2012FTC087406 Chennai, Tamil Nadu, India
Medroute Pharmaceuticals Private Limited U74900PB2014PTC038855 Hoshiarpur, Punjab, India
12

Who Uses This Report

CA · CS · Banker · Investor · Vendor
Chartered Accountants (CA)

Verify Relixir Pharmaceuticals Private Limited before audits and certifications: compliance score 68/100, filing history, auditor history and charge records in one place - instead of pulling each MCA form separately.

Company Secretaries (CS)

Track statutory health of Relixir Pharmaceuticals Private Limited: ACTIVE compliance status, annual-return recency, director DIN status, board churn and the events timeline - the inputs for secretarial audits and due-diligence certificates.

Bankers & NBFCs

Current banker verdict: Mixed indicators - deeper appraisal suggested. Credit risk score 45/100, existing charge position and lender relationships - a first-pass credit memo before formal appraisal.

Investors & Analysts

Investor view: Mixed indicators. Growth score 50/100, margin trends, ownership structure and peer set for Relixir Pharmaceuticals Private Limited - screening before a deeper diligence.

Vendors & Procurement Teams

Vendor verdict: Review suggested. Trust score 73/100, distress signals and MSME payment-delay disclosures - know whether Relixir Pharmaceuticals Private Limited pays its suppliers before you extend credit terms.

Lawyers & Compliance Teams

Litigation footprint (1 case(s) on record), regulatory flags, charge documents trail and director networks for Relixir Pharmaceuticals Private Limited - groundwork for KYC, onboarding and disputes.

13

Frequently Asked Questions

Is Relixir Pharmaceuticals Private Limited an active company?

Relixir Pharmaceuticals Private Limited has MCA status “Active” with a compliance score of 68/100 (Moderate).

Is Relixir Pharmaceuticals Private Limited financially healthy?

Relixir Pharmaceuticals Private Limited has a Financial Health Score of 55/100 (Moderate) based on its filed financial statements.

Should I do business with Relixir Pharmaceuticals Private Limited?

Its overall Trust Score is 73/100 (Moderate). Vendor verdict: Review suggested. Review the risk flags in the Risk Intelligence Center before deciding.

Who controls Relixir Pharmaceuticals Private Limited?

Promoters hold a dominant controlling stake - exact percentages are in the full report. 3 active director(s) are on record.

Does Relixir Pharmaceuticals Private Limited have loans or charges against its assets?

No open charges - all 3 registered charge(s) stand satisfied, indicating past borrowings were repaid.

Is Relixir Pharmaceuticals Private Limited up to date with its ROC filings?

Last balance sheet is for Mar 2023 - filings overdue. Overall compliance score: 68/100 (Moderate).

Is it risky to lend to Relixir Pharmaceuticals Private Limited?

Its Credit Risk Score is 45/100 (Caution Indicated). Banker verdict: Mixed indicators - deeper appraisal suggested.

Disclaimer: This report is generated automatically from MCA filings and public records as available in our system at the time of the last update. Scores, bands and verdicts are rule-based derived indicators of the underlying data - they are opinions generated by an algorithm, not statements of fact about the company, and are not credit ratings (within the meaning of SEBI regulations), audits, or investment, legal or financial advice. Verify from official sources and consult a qualified professional before any business, lending or investment decision. If you represent this company and believe any information is inaccurate or outdated, report it here and we will review promptly.